Sofosbuvir plus rivabirin showed efficacy in reducing viral load in patients infected with hepatitis C who are considered unlikely to respond to treatment, data show. No deaths were recorded, and no patients stopped treatment due to adverse events. The study was conducted by researchers at the National Institute of Allergy and Infectious Diseases.

Related Summaries